Study of free and complexed prostate-specific antigen in mice bearing human prostate cancer xenografts

✍ Scribed by Buhler, Kent R.; Corey, Eva; Stray, James E.; Vessella, Robert L.

• Publisher: John Wiley and Sons
• Year: 1998
• Tongue: English
• Weight: 202 KB
• Volume: 36
• Category: Article
• ISSN: 0270-4137
• DOI: 10.1002/(sici)1097-0045(19980801)36:3<194::aid-pros8>3.0.co;2-h

✦ Synopsis

Background:

Our objective was to evaluate five preclinical prostate cancer (cap) xenograft models to determine whether (1) prostate-specific antigen (psa) formed complexes in murine serum, (2) the percentage of free psa (f-psa) was characteristic of a given xenograft line, and (3) the percentage of f-psa was similar to that in the patient at time of tumor harvest. our fourth objective was to identify which murine serpin(s) bind(s) to psa in vivo.

Methods:

Xenografts were established from metastatic foci. the percentage of f-psa, and total psa (t-psa) in serum of animals bearing cap xenografts was determined by immunoassay. size exclusion high-performance liquid chromatography and western blots were used to evaluate the presence of psa complexes in murine serum. edman degradation was used to determine the n-terminal sequence of complexed proteins.

Results:

Psa was detected as both free and complexed forms in murine serum from all mice bearing the cap xenografts. three xenografts (related sublines) produced psa that resulted in low mean percentages of f-psa (1.9-6.4%). in sera from the other two xenografts, the mean percentages of f-psa were high (>25%); patient sera, where available at time of tumor acquisition, were in agreement. western blots showed that murine protease inhibitors formed complexes with psa. edman degradation yielded a sequence with 80% homology over 15 amino acids with that of murine alpha1-protease inhibitor (alpha1-pi).

Conclusions:

Our data have shown that the majority of psa secreted by these cap xenografts complexes in murine serum with a protease inhibitor with high homology to murine alpha1-pi and that the percentage of f-psa is a characteristic of each xenograft line tested, which is in agreement with patient values at time of tumor harvest. these cap xenografts offer opportunities for study of human psa biology and phenomenology.